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OBJECTIVES We performed a prospective, randomized, double-blind, placebo-controlled study of carve-
dilol effects in children with severe, chronic heart failure (HF), despite the use of conventional
therapy.
BACKGROUND Little is known about the effects of carvedilol in youngsters with chronic HF and severe left
ventricular (LV) dysfunction.
METHODS We conducted a double-blind, placebo-controlled study of 22 consecutive children with
severe LV dysfunction. The children had chronic HF and left ventricular ejection fraction
(LVEF) 30%. Patients were randomly assigned to receive either placebo (8 patients) or the
beta-blocker carvedilol (14 patients) at 0.01 mg/kg/day titrated up to 0.2 mg/kg/day,
followed-up for six months.
RESULTS During the follow-up and the up-titration period in the carvedilol group, four patients died
and one underwent heart transplantation. In patients receiving carvedilol evaluated after six
months, a significant increase occurred in LVEF, from 17.8% (95% confidence interval [CI],
14.1 to 21.4%) to 34.6% (95% CI, 25.2 to 44.0%); p  0.001. Modified New York Heart
Association (NYHA) functional class improved in nine patients taken off the transplant
waiting list. All nine patients were alive at follow-up. In the placebo group, during the
six-month follow-up, two patients died, and two underwent heart transplantation. Four
patients persisted with HF symptoms (NYHA functional class IV). No significant change
occurred in LVEF or fractional shortening.
CONCLUSIONS Carvedilol added to standard therapy may reduce HF progression and improve cardiac
function, allowing some youngsters to be removed from the heart transplantation waiting
list. (J Am Coll Cardiol 2002;40:2034–8) © 2002 by the American College of Cardiology
Foundation
In heart failure (HF) beta-adrenergic receptors associated
with the alpha-adrenergic system play important roles in
myocardial contractility and cellular remodeling (1,2). Beta-
blocking agents have been shown to reduce the risk of
hospitalization and death in patients with mild-to-moderate
HF (3,4).
In clinical trials, carvedilol, a nonselective third-
generation beta-blocker, vasodilator secondary to alpha1-
adrenergic blockade with antioxidant activity and apoptosis
inhibition, has been demonstrated to favorably affect survival in
adult patients with severe chronic HF (5–10), but very little is
known about its effects in infants and children (11).
We conducted a prospective, randomized, double-blind,
placebo-controlled study of the effect of the beta-blocker
carvedilol in children with severe chronic HF, despite the
use of conventional therapy.
METHODS
Study patients. All patients included in this study had
advanced HF, despite at least two months of treatment with
digoxin, diuretics (in sufficient doses to maintain patients
free of edema), angiotensin-converting enzyme (ACE) in-
hibitors (if tolerated), and a poor response to conventional
therapy. They had ejection fractions 30% and were re-
ferred for heart transplantation for treatment of idiopathic
dilated cardiomyopathy at the Heart Institute (InCor) of the
University of Sa˜o Paulo Medical School. Patients were
excluded if they had active myocarditis (excluded by endo-
myocardial biopsy); sustained ventricular tachycardia or
heart block not controlled by antiarrhythmic intervention or
a pacemaker; systemic arterial hypertension; progressive
systemic diseases causing cardiomyopathy; clinically impor-
tant hepatic or renal disease; were hemodynamically unsta-
ble and taking either alpha- or beta-adrenergic agonists or
antagonists, or were on ventilatory mechanical support, or
both.
The Ethics Committee of our hospital approved the
protocol, and written informed consent was obtained from
each legal guardian of all patients before the study.
Study procedures. After a baseline evaluation, all con-
secutive children included in this study were randomly
assigned to receive carvedilol or placebo. The allocation
ratio (of patients given carvedilol to patients given placebo)
was two-to-one. They underwent a double-blind up-titration
phase, in addition to their usual medications. Patients received
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an initial dosage of 0.01 mg/kg/day [0.13 mg/day (95%
confidence interval [CI], 0.08 to 0.19 mg/day)] of carvedilol
[0.14 mg/day (95% CI, 0.05 to 0.24 mg/day)] or placebo
[0.12 mg/day (95% CI, 0.07 to 0.16 mg/day)] for one week,
which was then increased (the dosage was double) at one-week
intervals (if tolerated), first to 0.02 mg/kg/day [0.20 mg/day
(95% CI, 0.12 to 0.29 mg/day); carvedilol 0.23 mg/day (95%
CI, 0.15 to 0.33 mg/day); placebo 0.23 mg/day (95% CI, 0.14
to 0.32 mg/day)], then to 0.04 mg/kg/day [0.44 mg/day (95%
CI, 0.25 to 0.62 mg/day); carvedilol 0.39 mg/day (95% CI,
0.32 to 0.45 mg/day); placebo 0.51 mg/day (95% CI, 0.34 to
0.69 mg/day)], proceeding in weekly steps to 0.08 mg/kg/day
[0.85 mg/day (95% CI, 0.49 to 1.21 mg/day); carvedilol
0.77 mg/day (95% CI, 0.66 to 0.88 mg/day); placebo
0.97 mg/day (95% CI, 0.6 to 1.35 mg/day)], then to
0.16 mg/kg/day [1.8 mg/day (95% CI, 1.05 to 2.56 mg/day);
carvedilol 1.67 mg/day (95% CI, 1.47 to 1.88 mg/day);
placebo 1.96 mg/day (95% CI, 1.22 to 2.7 mg/day)], and
finally to a target dose of 0.2 mg/kg/day [2.31 mg/day (95%
CI, 1.34 to 3.28 mg/day); carvedilol 2.17 mg/day (95% CI,
1.89 to 2.4 mg/day); placebo 2.49 mg/day (95% CI, 1.54 to
3.44 mg/day)], twice daily, if tolerated. During the up-titration
dosage period, patients were evaluated weekly after which
double-blind therapy was maintained for at least an additional
six months. During this time, patients were on standard
therapy with digoxin, diuretics, and ACE inhibitors. Adjust-
ment in the standard medical therapy was at the discretion of
the physicians.
Study parameters. After six months of follow-up, patients
were observed for the occurrence of death for cardiovascular
reasons, modified New York Heart Association (NYHA)
functional classification (11), decrease in the use of conven-
tional medications, and removal from the waiting list for
heart transplantation. Radionuclide ventriculography and
echocardiography were used to measure left ventricular
(LV) function, with results being compared with the pre-
treatment values. Left ventricular diastolic index (LVDI)
(LV diastolic diameter per body surface) and LV systolic
index (LV systolic diameter per body surface area) were also
compared before and after carvedilol treatment.
Statistics. All data are reported as means and 95% confi-
dence intervals (CI). Differences in baseline characteristics
of the two treatment groups were compared with the
Student t test and the Fisher exact test. When the protocol
was terminated, the statistical treatment was performed
whenever possible on patients who had completed the study
(more than six months of treatment). Comparison between
treatment profiles was performed with repeated-measures
analysis of variance (ANOVA). This analysis consisted of
evaluation for each variable if its mean profiles during the
study period were similar for the placebo and carvedilol
groups, in other words, if the mean profiles of each variable
for each group were parallel. If this hypothesis was not
rejected, the group effects (if the curves were coincident) and
the evaluation of condition effects (parallelism of the curves
in relation to the abscissa axis) were tested. Otherwise, the
analysis was carried out with multiple comparison of the
means. The measures were analyzed before and after treat-
ment. The variables tested were LV ejection fraction
(LVEF), fraction shortening (FS), LVDI, LV systolic
index, systolic and diastolic arterial pressures, the dosage of
furosemide, and ACE inhibitors. A value of p  0.05 was
considered statistically significant.
RESULTS
We enrolled 22 consecutive children, age 3.2 months to 10
years, who had severe LV systolic dysfunction. Character-
istics of the study population are listed in Table 1.
The carvedilol (14 patients) and placebo (8 patients)
groups were similar in all pretreatment characteristics with
respect to clinical, functional, and hemodynamic parame-
ters, except for gender. After randomization and the adjust-
ment of the carvedilol dosage to 0.2 mg/kg/day, the total
Abbreviations and Acronyms
ANOVA  repeated-measures analysis of variance
FS  fractional shortening
HF  heart failure
LV  left ventricular/ventricle
LVDI  left ventricular diastolic index
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association







Mean (95% CI) p Value
Age (yrs) 3.7 (1.1–6.2) 2.1 (1.4–2.8) NS
Gender (M/F) 7/1 4/10 0.02
Weight (kg) 12.1 (7.3–16.8) 9.2 (7.7–10.8) NS
NYHA functional class IV 8 (100%) 14 (100%)
LV ejection fraction (%) 19.4 (15.9–22.8) 16.7 (14.2–19.2) NS
Fraction shortening (%) 14.1 (11.2–17.0) 13.3 (11.3–15.2) NS
LV diastolic diameter index (mm/m2) 121.3 (93.9–148.6) 110.9 (97.2–124.5) NS
LV systolic diameter index (mm/m2) 103.2 (79.1–127.1) 97.3 (83.1–111.3) NS
Titration period (days) 61.7 (35.8–87.7) 59.8 (37.4–82.2) NS
CI  confidence interval; LV  left ventricle/ventricular; NYHA  New York Heart Association.
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results in the follow-up study period were similar in both
placebo and carvedilol groups.
Effects of carvedilol at follow-up. Compared with pa-
tients in the placebo group, those in the carvedilol group
had improved cardiac function as reflected by an increase in
LVEF measured with radionuclide ventriculography (Fig.
1) and FS measured with echocardiography (Fig. 2). In
addition, the carvedilol-group patients benefited clinically,
as shown by NYHA functional class improvement, with a
decrease in the dosage of furosemide (p  0.04) and no
change in the dosage of ACE inhibitors (p  0.09).
However, the functional class of patients in the placebo
group did not change, and a significant increase occurred in
the dosage of diuretics (p  0.01) used in this group.
During the six-month follow-up and the up-titration
period in the carvedilol group (mean follow-up 59.8 days
[95% CI 37.4 to 82.2 days]), four patients died ([three in
the up-titration period, mean dosage 0.04 mg/kg/day, one
after a mean period of 26 days [dosage 0.2 mg/kg/day]), and
one patient underwent heart transplantation [during the
up-titration period receiving a dosage of 0.09 mg/kg/day]).
In patients evaluated after six months (carvedilol dosage
0.2 mg/kg/day), treatment with the drug was associated
with no deaths. No significant change occurred in systemic
systolic arterial pressure 93 mm Hg (95% CI 83 to 104 mm
Hg) versus 98 mm Hg (95% CI 89 to 107 mm Hg), p 
0.96 or diastolic pressure 63 mm Hg (95% CI 56 to 71 mm
Hg) versus 67 mm Hg (95% CI 59 to 75 mm Hg), p 
0.41. The LVEF increased from 17.8% (95% CI 14.1 to
21.4%) to 34.6% (95% CI 25.2 to 44.0%) (p  0.001) (Fig.
1). The FS increased from 14.4% (95% CI 11.5 to 17.2%) to
21.3% (95% CI 16.0 to 26.4%) (p  0.001) (Fig. 2). No
significant change occurred in LVDI (p  0.08) (Fig. 3),
but systolic index decreased (p  0.001). The NYHA
functional class improved in nine patients. The clinical
status of nine patients who were removed from the trans-
plantation waiting list was NYHA functional class I in eight
patients and NYHA class II in one patient. All patients
were alive at mean follow-up of 593 days (95% CI 514 to
644 days).
In addition, no significant changes occurred while pa-
tients were on ACE inhibitors (p  0.09) when compared
with baseline, but a decrease occurred in the dosage of
furosemide (p  0.04). In the placebo group, during the
six-month follow-up (mean follow-up 139 days [95% CI 99
to 179 days], dosage 0.2 mg/kg/day), two patients died, and
two others underwent heart transplantation. Four patients
evaluated after six months of treatment persisted with
symptoms and signs of HF (all patients were in NYHA
functional class IV), with a significant increase in the dosage
of furosemide (p  0.01) but no change in the ACE
inhibitor dosage (p  0.09). No significant change occurred
in systemic systolic arterial pressure 90 mm Hg (95% CI 82
to 98 mm Hg) versus 85 mm Hg (95% CI 79 to 90 mm Hg,
p 0.96) or diastolic pressure 60 mm Hg versus 62 mm Hg
(95% CI 57 to 67 mm Hg), p  0.41. No increase occurred
in LVEF 21.3% (95% CI 16.4 to 26.0%) versus 19.3% (95%
CI 14.3 to 24.1%), p  0.71 (Fig. 1) or in FS 15.5% (95%
CI 9.8 to 21.2%) versus 14.0% (95% CI 10.7 to 17.3%), p
0.54 (Fig. 2). The mean LVDI increased significantly when
compared with that at baseline (p  0.01) (Fig. 3), and no
change occurred in LV systolic index (p  0.9).
Figure 1. Left ventricular ejection fraction (LVEF) by radionuclide ven-
triculography in the carvedilol and placebo groups.
Figure 2. Fractional shortening (FS) by echocardiogram in the carvedilol
and placebo groups.
Figure 3. Left ventricular diastolic index (LVDI) by echocardiogram in the
carvedilol and placebo groups.
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Safety. The discontinuation of treatment was not observed
in either group (carvedilol and placebo).
DISCUSSION
Our study indicates that the addition of carvedilol to
conventional therapy in children with dilated cardiomyop-
athy and severe LV dysfunction is associated with a marked
improvement in ventricular function. Patients have been
removed from the transplantation waiting list because of
their favorable response to carvedilol. Previous studies
(11–13) in children taking beta-blockers have reported
improvement in ventricular function; nevertheless, these
studies were not double-blinded or randomized, and they
did not recruit patients with severe congestive HF referred
for heart transplantation.
Our results demonstrate that significant decrease in the
final dosage required of the background medications (furo-
semide) was observed with the addition of carvedilol to our
armamentarium (14–16) in children with congestive HF.
Conversely, patients treated with placebo required an in-
crease in the dosage of diuretics owing to the worsening of
congestive HF. These results corroborate the findings of
other investigators in adult populations, showing that carve-
dilol may delay the worsening of HF (3,9,17).
The action mechanisms of beta-blocking agents in HF
are not fully understood. One mechanism is to prevent and
reverse adrenergically mediated intrinsic myocardial dys-
function and remodeling (2). However, carvedilol has addi-
tional properties (e.g., alpha-adrenergic blockade, antioxi-
dant activity, anti-endothelin effects) that may enhance its
ability to attenuate the adverse effects of the sympathetic
nervous system on circulation (6,18–25). These additional
actions may be particularly important in severe HF and may
determine the differences between the effects of carvedilol
and those of other beta-blocking agents (e.g., bucindolol)
(26). In addition, this study demonstrates that, despite some
differences in the pathophysiologic mechanisms of progres-
sive cardiac dysfunction in children, particularly neonates,
compared with that in adults, which involve cellular mech-
anisms of calcium regulation and excitation-contraction
coupling and physiologic responses relating to beta-
adrenergic receptors (27), carvedilol improved symptoms
and LV function in pediatric patients with HF. Therefore,
it may have similar mechanisms of action as that of
beta-blockers in adult populations.
After six months of treatment with carvedilol, no change
was noted in LVDI compared with that at baseline, but a
decrease occurred in systolic index. However, in the placebo
group, an increase did occur in the LVDI. These results are
consistent with those of a recent study (28) that showed the
beneficial effect of carvedilol on LV remodeling.
Other issues that may have influenced our results are the
type of pediatric cardiomyopathy amenable to beta-blocker
therapy, the optimal timing of beta-blocker therapy, and the
preferable type of beta-blockers to be used in children. In
the current study, we recruited only hemodynamically stable
patients with severe dilated cardiomyopathy referred for
heart transplantation. Carvedilol was our drug of choice
because it is one of the new-generation beta-blockers with
both beta-1 and beta-2 blocking properties and vasodilating
properties that may enhance their effects on HF in adult
populations (9).
The initiation of therapy with carvedilol in our study
produced no side effects consistent with its antiadrenergic
actions, so discontinuation of double-blind treatment was
not required. Thus, patients were able to tolerate the target
doses of carvedilol used. It must be emphasized, however,
that carvedilol therapy was initiated in the study with
extreme caution by physicians experienced in managing
heart failure to ensure the safety of the patient, because our
study recruited patients with severe LV dysfunction. To
enhance patient safety, therapy with carvedilol was initiated
in small doses that were gradually increased over a period of
several weeks. This cautious approach has been followed in
studies of other beta-blockers and is designed to minimize
the adverse effects that may occur after abrupt withdrawal of
the homeostatic support provided by the sympathetic ner-
vous system (2).
Heart transplantation has been the option for infants and
children with lethal cardiac disease. Although many efforts
have been made to decrease waiting-list mortality, including
breaching the barrier of ABO incompatibility (29,30),
effective strategies for managing severe HF in infants and
children with cardiomyopathy that could delay or even
eliminate the need for transplantation still remain the goal
of therapy in this group of patients. Therefore, our finding
that carvedilol improves ventricular function contributing to
the removal of children from the heart transplantation
waiting list supports the hypothesis that carvedilol can
favorably influence the course of disease in children with
severe LV dysfunction.
Study limitations. The baseline characteristics of treat-
ment groups were similar except for gender; however, this
probably reflects the number of patients recruited. Other-
wise, no evidence exists that gender is a predictor of
tolerability or an influence on the effects of carvedilol in
patients with chronic heart failure in the adult population
(31) or is an important determinant of prognosis in children
with idiopathic dilated cardiomyopathy (32–36).
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